Shopping Cart
Remove All
Your shopping cart is currently empty
Synonyms:
SARS-CoV-2 3CLpro-IN-35
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | SARS-CoV-2 3CLpro-IN-35 is an inhibitor of the SARS-CoV-2 3CL protease, with an IC50 of 0.15 μM. It inhibits the proliferation of bladder cancer cells and demonstrates anti-SARS-CoV-2 activity while exhibiting low cytotoxicity in fibroblasts. This compound is applicable in research related to SARS-CoV-2 infection and bladder cancer. |
| In vitro | SARS-CoV-2 3CLpro-IN-35 (Compound L3) effectively inhibits the infection of GFP-SARS-CoV-2-S-Psv in HK-2 cells, with an EC50 of 2.82 μM. Additionally, SARS-CoV-2 3CLpro-IN-35 (2-40 μM; 24 h) suppresses the proliferation of T24 bladder cancer cells in a concentration-dependent manner, with an IC50 of 10.99 μM. |
| Molecular Weight | 618.52 |
| Formula | C32H24F6O6 |
| Cas No. | 3023042-32-9 |
| Smiles | O=C(O)CCC=1C=C(C2=CC=C(C=C2)C(F)(F)F)C(O)=C(C1)C3=CC(=CC(C=4C=CC(=CC4)C(F)(F)F)=C3O)CCC(=O)O |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 µL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.